Moderna Reports Q2 Revenue Beat, Advances Flu Vaccine and Pipeline Amid Cost Cuts
The biotech exceeded Q2 revenue guidance and improved margins through efficiency gains while preparing for potential flu vaccine approval and multiple pipeline launches.
Revenue Beat Amid Seasonal Slowdown
Moderna reported second-quarter revenue of $145 million, exceeding its guidance range during what CEO Stéphane Bancel characterized as "always light for seasonal vaccines" (earnings call, 2026-07-31). The Cambridge-based biotech posted a net loss of $782 million, or $1.97 per share, an improvement from the $2.13 loss per share in the prior-year period.
The company maintained its full-year revenue growth guidance of up to 10% for 2026, with CFO Jamey Mock reiterating expectations for a roughly even split between U.S. and international sales. First-half revenue totaled $500 million, with 69% coming from international markets driven by long-term strategic partnerships (earnings call, 2026-07-31).
Cost Discipline and Improved Efficiency
Moderna achieved a 10% reduction in cash costs during Q2 compared to the second quarter of 2025, according to Bancel. The company lowered its full-year cost of sales projection by $100 million to $1.7 billion, reflecting manufacturing efficiency gains. R&D expenses also declined 7% year-over-year to $651 million, driven by the wind-down of several late-stage programs.
The company improved its total cash cost guidance by $200 million to $4 billion, excluding stock-based compensation, depreciation, and amortization. However, the Q2 cash position of $6.9 billion declined from $7.5 billion at the end of Q1. Mock noted that a $950 million litigation settlement payment in July would further impact the third-quarter cash balance (earnings call, 2026-07-31).
Flu Vaccine Advances Toward Approval
Moderna's seasonal flu vaccine, mRNA-1010, received a positive recommendation from the U.S. FDA's Vaccines and Related Biological Products Advisory Committee during the quarter. The unanimous vote represents "another important milestone ahead of our August 5 PDUFA date and brings us one step closer to potentially making our flu vaccine available to patients," Bancel said (earnings call, 2026-07-31).
The company's COVID-19 vaccine portfolio showed momentum, with mNEXSPIKE now approved in Japan and Taiwan. President Stephen Hoge highlighted that mNEXSPIKE captured approximately 24% of the total U.S. retail COVID vaccine market during its first season, with particularly strong uptake among adults 65 and older at 34% market share.
Real-world evidence presented on the call showed vaccine effectiveness of approximately 59% against hospitalization for adults 65 and older, rising to 67% for those 75 and older (earnings call, 2026-07-31).
Pipeline Progress and Leadership Changes
The company announced it has begun dosing in two cancer antigen therapy programs: a Phase I/II study of mRNA-4194 in Lynch syndrome and a Phase I study of mRNA-4200 in solid tumors. Moderna also presented five-year Phase II data for its individualized neoantigen therapy in combination with Keytruda for adjuvant melanoma at ASCO 2026.
Moderna appointed Ester Banque as Chief Commercial Officer, bringing more than 30 years of commercial leadership experience from Zoetis, Bristol Myers Squibb, and Novartis. The company also added Michael McDonald, former CFO of Biogen, to its board of directors.
The company projects ending 2026 with between $4.7 billion and $5.2 billion in cash and investments, an improvement from prior guidance (earnings call, 2026-07-31).
This article was generated by MarginX from the earnings call on 2026-07-31. It is not investment advice.